Matinas BioPharma Holdings Inc
$ 0.62
2.46%
24 Feb - close price
- Market Cap 4,003,900 USD
- Current Price $ 0.62
- High / Low $ 0.64 / 0.61
- Stock P/E N/A
- Book Value 1.09
- EPS -3.42
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.39 %
- ROE -1.52 %
- 52 Week High 3.09
- 52 Week Low 0.48
About
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, is focused on the discovery and development of several candidate products. The company is headquartered in Bedminster, New Jersey.
Analyst Target Price
$30.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-10 | 2025-08-13 | 2025-04-15 | 2025-03-25 | 2024-11-13 | 2024-08-07 | 2024-05-09 | 2024-01-09 | 2023-11-08 | 2023-08-09 | 2023-05-10 | 2023-03-15 |
| Reported EPS | -0.4 | -1.03 | -0.81 | -0.8056 | -0.85 | -0.02 | -0.03 | -0.02 | -0.03 | -0.03 | -0.03 | -0.02 |
| Estimated EPS | None | None | -0.78 | -0.78 | -1.05 | -0.02 | -0.03 | -0.03 | -0.03 | -0.03 | -0.03 | -0.03 |
| Surprise | 0 | 0 | -0.03 | -0.0256 | 0.2 | 0 | 0 | 0.01 | 0 | 0 | 0 | 0.01 |
| Surprise Percentage | None% | None% | -3.8462% | -3.2821% | 19.0476% | 0% | 0% | 33.3333% | 0% | 0% | 0% | 33.3333% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MTNB
2026-01-27 18:28:54
Matinas BioPharma Holdings Inc. announced that Keith Kucinski will resign as CFO effective January 17, 2026. Jerome D. Jabbour will assume the duties of Principal Accounting Officer and Interim Chief Financial Officer, effective January 22, 2026. These changes were also noted in a November 2025 SEC filing and press release.
2026-01-27 16:27:47
Matinas BioPharma announced that its CEO, Jerome D. Jabbour, has been appointed interim Chief Financial Officer following the resignation of Keith Kucinski. Jabbour, a co-founder with extensive experience, will maintain his existing leadership roles without changes to his employment terms. The company's stock, MTNB, currently holds a "Hold" rating from analysts with a $0.62 price target, despite weak financial performance and recurring losses.
2026-01-24 08:57:24
Matinas BioPharma Holdings, Inc. has announced the appointment of its current Chairman, President, and CEO, Jerome D. Jabbour, as interim Chief Financial Officer. This appointment follows the resignation of the previous CFO, Keith Kucinski. Jabbour will maintain his existing leadership roles while taking on the financial officer responsibilities until a permanent successor is found.
2026-01-24 07:28:35
Matinas BioPharma Holdings, Inc. has appointed its current Chairman, President, and CEO, Jerome D. Jabbour, as interim Chief Financial Officer. This appointment follows the resignation of the previous CFO, Keith Kucinski, who left to pursue other opportunities. Jabbour will maintain his existing roles while serving as interim CFO until a successor is found, with no changes to his compensation for these added responsibilities.
2026-01-24 05:57:58
Matinas BioPharma Holdings, Inc. (NYSE American:MTNB) announced the appointment of its current Chairman, President, and CEO, Jerome D. Jabbour, as interim Chief Financial Officer. This appointment follows the resignation of Keith Kucinski and is effective January 24, 2026. Jabbour will continue in his existing roles while serving as interim CFO until a successor is appointed.
2026-01-23 22:58:40
Matinas BioPharma Holdings, Inc. has appointed its current Chairman, President, and CEO, Jerome D. Jabbour, as interim Chief Financial Officer, effective immediately. This appointment follows the resignation of Keith Kucinski, who departed on January 17, 2026. Jabbour will maintain his existing leadership roles while also taking on the responsibilities of principal financial and accounting officer.
